Rett syndrome

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ventyx, Anavex, Checkpoint, and Sonder and Encourages Investors to Contact the Firm

Retrieved on: 
Wednesday, April 17, 2024
FDA, Radiation, Prospectus, MCI, CMO, Sonder, Crohn's disease, News, Food, Annual report, Complaint, Radar, Security (finance), Rett syndrome, Biologics license application, Form, P.C, IPO, Patient, Defendant, Acquisition, Psoriasis, CKPT, Inflammation, BLA, Register, Bank statement, CRL, Clinical trial, File, Pharmaceutical industry

The Company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.

Key Points: 
  • The Company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.
  • In addition, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects.
  • On November 6, 2023, during after-market hours, Ventyx issued a press release announcing results from the Phase 2 SERENITY Trial.
  • On this news, Checkpoint's stock price fell $1.49 per share, or 44.88%, to close at $1.83 per share on December 18, 2023.

SHAREHOLDER ALERT: Anavex Life Sciences Sued for Securities Law Violations; Investors Should Contact Block & Leviton for More Information

Retrieved on: 
Tuesday, April 16, 2024
Block & Leviton, Clinical trial, Rett syndrome, Patient, Certification, Cryptocurrency

BOSTON, April 16, 2024 (GLOBE NEWSWIRE) --  A class action lawsuit has been filed against Anavex Life Sciences Corp. (NASDAQ: AVXL) for securities law violations.

Key Points: 
  • BOSTON, April 16, 2024 (GLOBE NEWSWIRE) --  A class action lawsuit has been filed against Anavex Life Sciences Corp. (NASDAQ: AVXL) for securities law violations.
  • Investors who purchased shares and have lost money are encouraged to contact the firm to learn more about how they might recover those losses.
  • The study failed to show statistical significance towards its primary endpoints, causing shares of Anavex Life Sciences Corp. stock to drop approximately 35%.
  • Block & Leviton is widely regarded as one of the leading securities class action firms in the country.

ANAVEX LIFE SCIENCES CORPORATION (NASDAQ: AVXL) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Anavex Life Sciences Corporation

Retrieved on: 
Monday, April 15, 2024
FDA, News, Central nervous system disease, Complaint, Rett syndrome, Neurodevelopmental disorder, Research, CNS, Avatar, Action Replay, District court, Patient, Court, Central nervous system, Advertising, Excellence

NEW YORK, April 15, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP:

Key Points: 
  • NEW YORK, April 15, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP:
    Do you, or did you, own shares of Anavex Life Sciences Corporation (NASDAQ: AVXL)?
  • If you wish to serve as lead plaintiff, you must move the Court no later than May 13, 2024.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ventyx, Anavex, and Checkpoint and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, April 13, 2024
FDA, Radiation, Prospectus, MCI, CMO, Crohn's disease, News, Food, Complaint, Radar, Security (finance), Rett syndrome, Biologics license application, Form, P.C, IPO, Patient, Defendant, Acquisition, Psoriasis, CKPT, Inflammation, BLA, Register, CRL, Clinical trial, File, Pharmaceutical industry

The Company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.

Key Points: 
  • The Company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.
  • In addition, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects.
  • cites findings that arose during a multi-sponsor inspection of Checkpoint's third-party [CMO] as approvability issues to address in a resubmission."
  • On this news, Checkpoint's stock price fell $1.49 per share, or 44.88%, to close at $1.83 per share on December 18, 2023.

Acadia Pharmaceuticals is Proud to Announce the Winners of the Inaugural Rett Sibling Scholarship

Retrieved on: 
Monday, April 29, 2024
Research, Mental Health, Neurology, Clinical Trials, Biotechnology, University, Pharmaceutical, Health, Science, Education, Sibling, Rett, Rett syndrome, Parent, Life, Psychology, Medicine, Student, ISTS, Social justice, ACAD

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it has awarded 10 academic scholarships to eligible recipients of the first Rett Sibling Scholarship.

Key Points: 
  • Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it has awarded 10 academic scholarships to eligible recipients of the first Rett Sibling Scholarship.
  • The Rett Sibling Scholarship program, sponsored by Acadia, was established in 2023 to recognize the siblings of individuals with Rett syndrome.
  • “In establishing the Rett Scholarship program Acadia seeks to recognize their resilience and contributions while providing support in pursuit of their academic goals.
  • “The Rett Sibling Scholarship recognizes my personal aspirations, which are inspired by my relationship with my sister, and reminds me that siblings like me are not alone in our journeys,” said Kate Koblegarde, one of this year’s Rett Sibling Scholarship recipients.

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Anavex Life Sciences Corporation (AVXL) Shareholders

Retrieved on: 
Thursday, April 11, 2024
MCI, LLP, News, CLASS, Radar, NEXT, Rett syndrome, Patient, Court, Clinical trial, Telephone, COST, Cryptocurrency

NEW YORK, April 11, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Anavex Life Sciences Corporation ("Anavex Life Sciences" or the "Company") (NASDAQ: AVXL) of a class action securities lawsuit.

Key Points: 
  • NEW YORK, April 11, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Anavex Life Sciences Corporation ("Anavex Life Sciences" or the "Company") (NASDAQ: AVXL) of a class action securities lawsuit.
  • CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Anavex Life Sciences investors who were adversely affected by alleged securities fraud between February 1, 2022 and January 1, 2024.
  • Follow the link below to get more information and be contacted by a member of our team:
    AVXL investors may also contact Joseph E. Levi, Esq.
  • For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

Anavex Life Sciences to Present at the Noble Capital Markets Virtual Healthcare Equity Conference

Retrieved on: 
Thursday, April 11, 2024
Rett syndrome, Doctor of Philosophy, Conference, CNS, Schizophrenia, Therapy, DSM-IV codes, Central nervous system, Noble

NEW YORK, April 11, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome, schizophrenia and other central nervous system (CNS) diseases, today announced that it will present at the Noble Capital Markets Virtual Healthcare Equity Conference.

Key Points: 
  • NEW YORK, April 11, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome, schizophrenia and other central nervous system (CNS) diseases, today announced that it will present at the Noble Capital Markets Virtual Healthcare Equity Conference.
  • Christopher U Missling, PhD, President & Chief Executive Officer is scheduled to present at 1:30pm ET, TRACK 2 on Thursday, April 18th, 2024.
  • A live audio webcast will be accessible through the Investors section of the Company’s website at www.anavex.com .
  • An archived edition of the session will be available later that day.

AVXL INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Anavex Life Sciences Corp. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Retrieved on: 
Thursday, April 11, 2024
FDA, News, Central nervous system disease, Complaint, Rett syndrome, Neurodevelopmental disorder, Research, CNS, Avatar, Patient, Court, Central nervous system, Excellence, Person, Fraud, Pharmaceutical industry

Anavex has sponsored several research studies concerning blarcamesine’s suitability to treat various CNS disorders.

Key Points: 
  • Anavex has sponsored several research studies concerning blarcamesine’s suitability to treat various CNS disorders.
  • or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660.
  • If you suffered a loss in Anavex you have until May 13, 2024, to request that the Court appoint you as lead plaintiff.
  • Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 13, 2024 in Anavex Life Sciences Corporation Lawsuit – AVXL

Retrieved on: 
Wednesday, April 10, 2024
MCI, News, Radar, NEXT, Rett syndrome, Patient, Clinical trial, Fraud, Security (finance)

NEW YORK, April 10, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Anavex Life Sciences Corporation (NASDAQ: AVXL).

Key Points: 
  • NEW YORK, April 10, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Anavex Life Sciences Corporation (NASDAQ: AVXL).
  • Shareholders who purchased shares of AVXL during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
  • Appointment as lead plaintiff is not required to partake in any recovery.
  • The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship.

Acadia Pharmaceuticals Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health Canada

Retrieved on: 
Monday, April 22, 2024
Health, Neurology, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Sale, NDS, Priority review, Safety, Woman, Rett syndrome, Neurodevelopmental disorder, Health Canada, Communication, Patient, Caregiver, Diagnosis, ACAD, Pharmaceutical industry

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Health Canada has accepted its New Drug Submission (NDS) for trofinetide for the treatment of Rett syndrome, a rare neurodevelopmental disorder.

Key Points: 
  • Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Health Canada has accepted its New Drug Submission (NDS) for trofinetide for the treatment of Rett syndrome, a rare neurodevelopmental disorder.
  • Health Canada has granted Priority Review for Acadia’s submission.
  • is pleased that Health Canada has granted Priority Review for this promising treatment which, if approved, would be a significant step forward in addressing the unmet medical needs of Canadians living with Rett syndrome,” said Sabrina Millson, President of the Ontario Rett Syndrome Association (O.R.S.A.).
  • Trofinetide has been approved for the treatment of Rett syndrome in adult and pediatric patients two years of age and older in the United States, and it is not currently authorized for sale in Canada for the treatment of Rett syndrome.